Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HHS Nominee Azar: Great News For Industry But ACA Reform Will Be Priority

Executive Summary

Insurance practices are a big driver of drug pricing problems, according to Azar, a former Lilly exec who spent six years at HHS under George W. Bush, providing him valuable experience in department operations.

Advertisement

Related Content

OMB's Grogan Talks Drug Pricing And Taking On 'Sacred Cows'
HHS Leadership Upheaval Could Delay Initiatives Impacting Biopharma
Drug Payment Experiments Coming To Medicare, Medicaid
Trump Exec Order On Drug Costs: Seeking To Balance Access, Innovation
Lilly, Anthem Singing Same Tune On Value-Based Pricing, Communication Policy

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS121956

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel